Ozempic on the NHS: Eligibility Criteria, Costs, and the Prescribing Pathway

NHS prescribing of Ozempic follows NICE NG 28 guidelines for managing type 2 diabetes in adults. The criteria have evolved to give prescribers more flexibility, but core requirements remain.

Standard NICE NG 28 criteria for GLP-1 receptor agonists:

• Confirmed diagnosis of type 2 diabetes mellitus
• HbA1c above 58 mmol/mol (7.5%) despite optimised first-line therapy (metformin titrated to maximum tolerated dose)
• At least one other glucose-lowering drug has been tried in combination with metformin, or alternative drugs have been tried if metformin is contraindicated or not tolerated
• BMI of 35 kg/m2 or greater with specific psychological or medical problems associated with obesity, or BMI below 35 kg/m2 where insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities

Expanded prescribing considerations:

NICE has acknowledged the cardiovascular benefits demonstrated in SUSTAIN 6 and allows prescribers to factor in cardiovascular risk when choosing between second-line options.

This means patients with established atherosclerotic cardiovascular disease or high cardiovascular risk may be offered a GLP-1 agonist preferentially, regardless of BMI.

Who does not qualify:

• Patients without type 2 diabetes. Weight management is covered by separate NICE guidance (TA 875 for Wegovy)
• Type 1 diabetes. GLP-1 agonists have no approved role
• Patients who have not explored first-line and second-line options where appropriate
• Pregnancy or planned pregnancy within 2 months

The route to obtaining an Ozempic prescription on the NHS typically involves a structured pathway that may require specialist input.

Step 1: GP assessment and first-line treatment

Your GP diagnoses type 2 diabetes and starts metformin. Lifestyle modification advice (diet, exercise, weight management) is provided alongside medication. HbA1c is reviewed at 3 to 6 months.

Step 2: Second-line therapy consideration

If HbA1c remains above 58 mmol/mol, a second drug is added. Options include sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors, pioglitazone, or GLP-1 receptor agonists.

The choice depends on individual patient factors.

Step 3: GLP-1 agonist initiation

• In some areas, GPs can initiate GLP-1 agonists directly using local formulary guidance
• In other Integrated Care Board areas, initiation requires referral to a diabetes specialist (consultant diabetologist or specialist nurse)
• Some areas have virtual clinics or advice-and-guidance services that allow GPs to start treatment with remote specialist support

Step 4: Shared care and ongoing prescribing

• After the titration phase (typically 8 to 12 weeks), prescribing is usually transferred back to the GP under a shared care agreement
• The GP provides repeat prescriptions and monitors weight, HbA1c, and side effects
• Annual specialist review may be required in some areas

Regional variation:

Prescribing criteria and initiation pathways vary between Integrated Care Boards. Some areas have more restrictive local formularies that preference alternative GLP-1 agonists (e.g.

dulaglutide) over semaglutide based on cost or supply considerations.

Understanding prescription charges helps patients plan financially for their treatment.

Current NHS prescription charges (England, 2026):

• Standard charge: 9.90 GBP per prescription item
• Ozempic pens are dispensed as one item per prescription, regardless of whether it is a Pen 1 (0.25/0.5 mg) or Pen 2 (1 mg)
• Needles are prescribed separately but are also charged as one item

Prescription prepayment certificates (PPC):

• 3-month PPC: approximately 32 GBP, covering unlimited prescriptions
• 12-month PPC: approximately 111 GBP
• For patients on Ozempic plus other regular medications, a PPC almost always saves money

Exemptions from prescription charges:

• Patients with diabetes who are treated with medication (insulin or oral hypoglycaemics) qualify for a medical exemption certificate. This covers all prescriptions, not just diabetes medications
• Apply using form FP92A, available from your GP surgery
• The exemption covers Ozempic, needles, blood glucose testing supplies, and all other medications
• Wales, Scotland, and Northern Ireland do not charge for NHS prescriptions

Important: diabetes exemption application

• You must apply proactively. The exemption is not automatic
• Your GP or practice nurse signs the form confirming your diabetes diagnosis and treatment
• The certificate is valid for 5 years and must be renewed
• If you hold a valid exemption certificate, tick the exemption box on the back of each prescription form

Most patients with type 2 diabetes on Ozempic should be paying nothing for their prescriptions if they have applied for and received their medical exemption certificate.

NICE NG 28 mandates regular review of GLP-1 receptor agonist therapy to confirm ongoing clinical benefit and justify continued prescribing.

6-month review (after reaching maintenance dose):

• HbA1c: the primary measure of treatment response. NICE previously required an 11 mmol/mol (1.0%) reduction for continuation. Current guidance considers broader benefits
• Body weight: weight loss supports continued prescribing even if HbA1c targets are not fully met
• Side effect assessment: persistent GI symptoms, injection site reactions, or other concerns
• Blood glucose diary review if self-monitoring

Annual diabetes review (standard care):

• HbA1c (target typically 48 to 58 mmol/mol depending on individual circumstances and hypoglycaemia risk)
• Blood pressure (target below 140/80 mmHg, or below 130/80 mmHg if kidney disease, eye disease, or cerebrovascular disease)
• Lipid profile: total cholesterol, LDL, HDL, triglycerides
• Renal function: eGFR and urine albumin:creatinine ratio
• Foot examination: pulses, sensation, skin integrity
• Retinal screening: annual digital retinal photography through the DESP
• Cardiovascular risk assessment
• Mental health and wellbeing check
• Injection technique review and site rotation assessment

Stopping criteria:

Your prescriber may consider discontinuing Ozempic if:

• HbA1c has not improved meaningfully and there is no significant weight loss after 6 to 12 months at maximum tolerated dose
• Intolerable side effects persist despite management strategies
• The patient's clinical circumstances change (e.g. pregnancy planning, terminal diagnosis)
• An alternative treatment becomes more appropriate based on emerging evidence or new medications

Patients on Ozempic should engage actively with NHS diabetes services to maximise treatment benefit.

Structured education programmes:

• DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed): a group education programme available through most NHS trusts for patients with type 2 diabetes
• X-PERT Diabetes: an alternative structured education programme offered in some areas
• NICE NG 28 recommends that all patients with type 2 diabetes are offered structured education at diagnosis. Attending improves outcomes and treatment adherence

Dietetic support:

• Request a referral to an NHS dietitian, particularly in the first 3 months of Ozempic treatment when appetite suppression may lead to inadequate nutrition
• Dietitians can help ensure adequate protein intake (at least 1.2 g/kg/day) and micronutrient sufficiency during weight loss

Diabetes specialist nurse access:

• Many GP practices have access to diabetes specialist nurses who can provide injection technique training, dose titration advice, and ongoing support
• Some areas offer telephone or virtual clinic follow-up between face-to-face appointments

NHS app and digital services:

• Order repeat prescriptions through the NHS App
• View test results (HbA1c, blood pressure, cholesterol) online
• Book GP appointments for diabetes reviews

Self-management essentials:

• Keep a record of your weight (weekly) and any side effects to discuss at reviews
• Carry your diabetes identification (medical exemption certificate or diabetes UK ID card)
• Know the signs of hypoglycaemia, even though the risk with Ozempic plus metformin is low
• Attend all screening appointments (retinal, foot, renal) as scheduled

Several common concerns arise in clinical practice regarding NHS access to Ozempic. Addressing these directly helps patients navigate the system.

"My GP refused to prescribe Ozempic. What can I do?"

GPs prescribe according to local formulary guidance and NICE criteria. If you believe you meet the criteria, ask your GP to explain the specific reason for refusal.

You can request a referral to a diabetes specialist for a second opinion. You also have the right to see a different GP within the same practice.

"I have been switched from Ozempic to another drug because of supply issues."

This is a recognised problem. Your prescriber should document that the switch was supply-driven, not clinically motivated, and plan to switch you back when supply normalises.

If you were well controlled on Ozempic, request a review within 3 months to assess the alternative.

"Can I get Ozempic for weight loss through the NHS?"

Not through Ozempic specifically.

If you meet the criteria for obesity treatment (BMI 30 or higher, or 27 or higher with comorbidities), ask your GP for referral to a specialist weight management service. Wegovy (semaglutide 2.

4 mg) is available through these services under NICE TA 875.

"The waiting list for diabetes specialist clinic is months long."

Ask your GP whether advice-and-guidance services or virtual specialist review are available locally. Some areas offer pharmacist-led GLP-1 initiation clinics to reduce specialist waiting times.

"I started Ozempic privately. Can my GP continue prescribing on the NHS?"

This depends on local shared care agreements. Some GPs will accept responsibility if you meet NHS criteria. Others may decline.

Discuss with your GP before assuming NHS continuation of private initiation.